Verve Therapeutics Inc.
13F holders, Q3 2025 (September 30)3holders +2
2new positions
0sold out
$11.00avg. 13F price*
At the end of Q3 2025, 3 institutions reported holding Verve Therapeutics Inc. in their 13F filings, up 2 from Q2 2025. 2 opened new positions and 0 sold out. The largest holders were Cim Investment Management Inc. ($287K), GAMMA Investing LLC ($0) and Murphy & Mullick Capital Management Corp ($0).
- Company
- Verve Therapeutics Inc.
- Filed as
- Contra Verve Therapeutic (Q3 2025)
- CUSIP
- 925CVR011
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $287K |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q3 2025: 26,004 shares bought, net +26,004 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Cim Investment Management Inc. | 0.08% | New | 25,747 | $287K |
| GAMMA Investing LLC | 0.00% | New | 257 | $0 |
| Murphy & Mullick Capital Management Corp | 0.00% | No change | 43 | $0 |
"% of holder's portfolio" is VERVE THERAPEUTICS INC's weight in each manager's 13F, not the share of Verve Therapeutics Inc. the manager owns.